Veradermics, Inc.(MANE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MANE Veradermics, Inc.

交易中 11-09 10:58:34 EST

143.47

+4.69

+3.38%

最高143.74	最低131.39	成交量13.12万
今开135.71	昨收138.78	日振幅8.90%
总市值59.94亿	流通市值46.33亿	总股本4,178万
成交额1,831万	换手率0.41%	流通股本3,229万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MANE","market":"US","secType":"STK","nameCN":"Veradermics, Inc.","latestPrice":143.465,"timestamp":1794239903734,"preClose":138.78,"halted":0,"volume":131194,"delay":0,"changeRate":0.033758466637844084,"floatShares":32290700,"shares":41778687,"eps":-6.443948,"marketStatus":"交易中","change":4.685,"latestTime":"11-09 10:58:34 EST","open":135.71,"high":143.74,"low":131.385,"amount":18305048.82458,"amplitude":0.089026,"askPrice":145.15,"askSize":100,"bidPrice":143,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-6.443948,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1794258000000},"marketStatusCode":2,"adr":0,"listingDate":1770181200000,"exchange":"NYSE","adjPreClose":138.78,"preHourTrading":{"tag":"盘前","latestPrice":135.1,"preClose":138.78,"latestTime":"09:29 EST","volume":4433,"amount":624076.7204100001,"timestamp":1794234565763,"change":-3.68,"changeRate":-0.026517,"amplitude":0.188779},"postHourTrading":{"tag":"盘后","latestPrice":139.33,"preClose":138.78,"latestTime":"19:48 EST","volume":4405,"amount":611515.9131,"timestamp":1794012480532,"change":0.55,"changeRate":0.003963,"amplitude":0.009151},"volumeRatio":0.949635,"impliedVol":0.5401,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/MANE","defaultTab":"news","newsList":[{"id":"1189503592","title":"异动解读｜Veradermics盘中上涨5.08%，获机构上调目标价支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1189503592","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189503592?lang=zh_cn&edition=full","pubTime":"2026-11-03 22:48","pubTimestamp":1793717291,"startTime":"0","endTime":"0","summary":"11月3日，Veradermics盘中上涨5.08%，报136.9125美元/股，成交额646.12万美元。消息面上，较新的明确催化来自10月22日，B. Riley将Veradermics目标价上调至204美元，维持买入评级。截至6月30日，公司现金、现金等价物及有价证券为8.199亿美元，称可支持运营至2030年并覆盖多项三期读出及VDPHL01潜在商业化。VeraDermics, Incorporated成立于2019年，是一家由皮肤科医生创办的晚期临床阶段生物制药公司，聚焦模式性脱发等皮肤疾病疗法开发，核心候选药物为口服非激素治疗VDPHL01。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"获上调目标价，Veradermics盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138341341","title":"异动解读｜Veradermics盘中下跌5.11%，报132.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138341341","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138341341?lang=zh_cn&edition=full","pubTime":"2026-11-03 00:15","pubTimestamp":1793636122,"startTime":"0","endTime":"0","summary":"11月3日，Veradermics盘中下跌5.11%，报132.56美元/股，成交额1963.63万美元。Veradermics所在的制药行业中，礼来跌1.02%，强生跌1.79%，默沙东跌1.13%，辉瑞跌0.15%，赛诺菲安万特涨1.22%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142832799","title":"异动解读｜Veradermics盘中上涨5.01%，临床进展与现金储备持续提供支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1142832799","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142832799?lang=zh_cn&edition=full","pubTime":"2026-10-21 21:48","pubTimestamp":1792590533,"startTime":"0","endTime":"0","summary":"10月21日，Veradermics盘中上涨5.01%，报133.4799美元/股，成交额518.93万美元。消息面上，市场仍在交易公司核心候选药物VDPHL01的积极临床进展，以及相对充裕的现金储备。已披露信息显示，VDPHL01在男性型脱发Ⅱ/Ⅲ期试验中达到所有主要及关键次要终点；女性型脱发Ⅱ期研究中，多数受试者在6个月后出现改善，且未见治疗相关严重不良事件或心脏不良事件。财务方面，公司上次披露期末现金及有价证券约8.199亿美元，管理层称可支持运营至2030年。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"临床数据亮眼，Veradermics盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156683736","title":"异动解读｜Veradermics盘中上涨5.26%，临床进展与现金储备持续提供支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1156683736","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156683736?lang=zh_cn&edition=full","pubTime":"2026-10-20 23:20","pubTimestamp":1792509647,"startTime":"0","endTime":"0","summary":"10月20日，Veradermics盘中上涨5.26%，报128.03美元/股，成交额4634.13万美元。消息面上，市场仍在交易公司核心候选药物VDPHL01的积极临床进展，以及相对充裕的现金储备。已披露信息显示，VDPHL01在男性型脱发Ⅱ/Ⅲ期试验中达到所有主要及关键次要终点；女性型脱发Ⅱ期研究中，多数受试者在6个月后出现改善，且未见治疗相关严重不良事件或心脏不良事件。财务方面，公司上次披露期末现金及有价证券约8.199亿美元，管理层称可支持运营至2030年。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Veradermics盘中上涨，脱发新药临床数据亮眼","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164093208","title":"异动解读｜Veradermics盘前上涨11.38%，临床进展与现金储备持续提供支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1164093208","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164093208?lang=zh_cn&edition=full","pubTime":"2026-10-20 16:00","pubTimestamp":1792483242,"startTime":"0","endTime":"0","summary":"10月20日，Veradermics盘前上涨11.38%，报128.5307美元/股，成交额7.76万美元。消息面上，市场仍在交易公司核心候选药物VDPHL01的积极临床进展，以及相对充裕的现金储备。已披露信息显示，VDPHL01在男性型脱发Ⅱ/Ⅲ期试验中达到所有主要及关键次要终点；女性型脱发Ⅱ期研究中，多数受试者在6个月后出现改善，且未见治疗相关严重不良事件或心脏不良事件。财务方面，公司上次披露期末现金及有价证券约8.199亿美元，管理层称可支持运营至2030年。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"脱发新药临床进展亮眼，盘前大涨引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171651429","title":"异动解读｜Veradermics夜盘上涨11.38%，临床进展与现金储备持续提供支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1171651429","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171651429?lang=zh_cn&edition=full","pubTime":"2026-10-20 12:56","pubTimestamp":1792472207,"startTime":"0","endTime":"0","summary":"10月20日，Veradermics夜盘上涨11.38%，报136.2美元/股，成交额18.59万美元。消息面上，市场仍在交易公司核心候选药物VDPHL01的积极临床进展，以及相对充裕的现金储备。已披露信息显示，VDPHL01在男性型脱发Ⅱ/Ⅲ期试验中达到所有主要及关键次要终点；女性型脱发Ⅱ期研究中，多数受试者在6个月后出现改善，且未见治疗相关严重不良事件或心脏不良事件。财务方面，公司上次披露期末现金及有价证券约8.199亿美元，管理层称可支持运营至2030年。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Veradermics夜盘大涨，脱发新药临床数据亮眼","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135817509","title":"异动解读｜Veradermics盘中上涨8.14%，近期临床进展与现金储备提供支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1135817509","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135817509?lang=zh_cn&edition=full","pubTime":"2026-10-19 21:42","pubTimestamp":1792417349,"startTime":"0","endTime":"0","summary":"10月19日，Veradermics盘中上涨8.14%，报118.65美元/股，成交额3040.77万美元。公开消息面看，公司近期股价曾在10月8日大涨23%并创历史新高，市场焦点仍围绕核心候选药物VDPHL01的临床推进。此前公司披露，VDPHL01在男性型脱发Ⅱ/Ⅲ期试验中达到所有主要及关键次要终点；女性型脱发Ⅱ期研究亦显示多数受试者在6个月后获得改善，且安全性良好。财务方面，公司二季度净亏损2350万美元，好于市场预期，期末现金及有价证券约8.199亿美元，称可支持运营至2030年。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Veradermics盘中上涨，脱发新药临床进展亮眼","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129616363","title":"异动解读｜Veradermics盘中上涨5.65%，口服脱发药物数据积极且现金充裕","url":"https://stock-news.laohu8.com/highlight/detail?id=1129616363","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129616363?lang=zh_cn&edition=full","pubTime":"2026-10-10 01:07","pubTimestamp":1791565627,"startTime":"0","endTime":"0","summary":"10月10日，Veradermics盘中上涨5.65%，报133.78美元/股，成交额6369.15万美元。公司核心候选药物VDPHL01为口服非激素脱发疗法，此前在男性和女性雄激素性脱发临床试验中均取得积极结果，女性Ⅱ期研究显示6个月后改善率最高达90.0%且安全性良好。此外，公司现金储备达8.199亿美元，预计可支持运营至2030年并覆盖多个Ⅲ期数据读出，为后续研发及潜在商业化提供较强资金保障。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"口服脱发药数据积极，Veradermics盘中上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162280779","title":"异动解读｜Veradermics盘中上涨17.35%，创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1162280779","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162280779?lang=zh_cn&edition=full","pubTime":"2026-10-09 00:45","pubTimestamp":1791477907,"startTime":"0","endTime":"0","summary":"10月8日，Veradermics盘中上涨17.35%，报130.215美元，成交额2.89亿美元，创下自4月以来最大单日涨幅。公司专注于脱发治疗，核心候选药物VDPHL01为口服非激素疗法。此前该药物在男性和女性雄激素性脱发临床试验中均取得积极结果，女性Ⅱ期研究显示受试者6个月后改善率最高达90.0%，且安全性良好。公司现金储备达8.199亿美元，预计可支持运营至2030年并覆盖多个Ⅲ期数据读出及VDPHL01的潜在商业化。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"脱发新药临床数据亮眼，Veradermics股价大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673003387","title":"Veradermics 股价大涨 23% 创历史新高，为 4 月以来最大单日涨幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2673003387","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673003387?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:05","pubTimestamp":1791468343,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651465277","title":"Veradermics女性脱发新药Ⅱ期临床取得积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2651465277","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651465277?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:04","pubTimestamp":1784120640,"startTime":"0","endTime":"0","summary":"Veradermics公司公布了其口服药物VDPHL01治疗女性轻中度脱发的Ⅱ期临床试验积极结果。　　Study 207是一项开放标签Ⅱ期临床试验，共纳入28名成年女性受试者，分别接受VDPHL01 4.5mg每日一次或每日两次给药，持续6个月。　　VDPHL01是一种新型口服缓释米诺地尔制剂，目前正同步开展男性和女性雄激素性脱发的注册临床试验。Veradermics于7月15日上午召开了投资者电话会议，讨论Study 207的详细结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-15/doc-inihxaeu7874849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135661380","title":"Veradermics旗下Vdphl01展现良好安全性，无治疗相关严重不良事件或心脏不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1135661380","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135661380?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:07","pubTimestamp":1784113624,"startTime":"0","endTime":"0","summary":"Veradermics公司宣布，其候选药物Vdphl01在一项研究中展现出良好的安全性特征。研究数据显示，该药物未引发任何与治疗相关的严重不良事件，亦未观察到心脏不良事件。这一结果初步验证了该疗法的安全性，为其后续临床开发提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146038381","title":"Veradermics口服药物Vdphl01在女性型脱发治疗中取得积极“207”二期临床结果，为即将揭晓的“306”二/三期研究数据铺路","url":"https://stock-news.laohu8.com/highlight/detail?id=1146038381","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146038381?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:02","pubTimestamp":1784113323,"startTime":"0","endTime":"0","summary":"Veradermics, Inc. 旗下口服药物Vdphl01在针对女性型脱发的二期临床研究“207”中取得了令人鼓舞的成果。这一积极数据的公布，恰逢其更为关键的后续二/三期研究“306”的数据读出来临前夕，为公司在脱发治疗领域的进展增添了重要砝码。研究“207”的正面结果不仅验证了Vdphl01在目标患者群体中的潜力，也为即将到来的“306”研究数据解读奠定了乐观预期。投资者与行业观察者正密切关注这一系列临床数据的连贯性，以期评估Vdphl01最终商业化的前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veradermics.com","stockEarnings":[{"period":"1week","weight":-0.0065},{"period":"1month","weight":0.2508},{"period":"3month","weight":0.2132},{"period":"6month","weight":0.3075},{"period":"1year","weight":7.1635},{"period":"ytd","weight":7.1635}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"VeraDermics, Incorporated成立于2019年10月5日，最初位于德克萨斯州，后于2021年9月15日转换为特拉华州公司。这家由皮肤科医生创办的晚期临床阶段生物制药公司专注于开发针对普遍存在的美学和皮肤病状况的创新疗法。VeraDermics主要致力于解决影响美国众多个体的模式性脱发（PHL）治疗挑战。公司目前正在推进其主要候选药物VDPHL01，这是一种口服非激素治疗，旨在优化毛发生长，同时最小化与传统疗法相关的副作用。VeraDermics正在进行关键临床试验，以支持监管审批，并通过其针对性的治疗方法，旨在改变PHL的管理方式。","exchange":"NYSE","name":"Veradermics, Inc.","nameEN":"Veradermics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Veradermics, Inc.(MANE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Veradermics, Inc.(MANE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Veradermics, Inc.,MANE,Veradermics, Inc.股票,Veradermics, Inc.股票老虎,Veradermics, Inc.股票老虎国际,Veradermics, Inc.行情,Veradermics, Inc.股票行情,Veradermics, Inc.股价,Veradermics, Inc.股市,Veradermics, Inc.股票价格,Veradermics, Inc.股票交易,Veradermics, Inc.股票购买,Veradermics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Veradermics, Inc.(MANE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Veradermics, Inc.(MANE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}